Letrozol Teva (Letrozole)

Letrozol Teva is an aromatase inhibitor used in the management of hormone‑dependent breast cancer. It works by reducing estrogen production, which slows tumor growth.

• Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer in postmenopausal women: helps prevent disease recurrence after surgery.
• First‑line therapy for advanced or metastatic hormone receptor‑positive breast cancer in postmenopausal women: slows disease progression.
• Extended adjuvant therapy after five years of tamoxifen in postmenopausal women: reduces risk of late recurrence.

• Letrozole selectively binds to the aromatase enzyme, a non‑steroidal inhibitor that blocks the conversion of androgens to estrogens in peripheral tissues. By decreasing systemic estrogen levels, it deprives estrogen‑dependent tumor cells of a growth stimulus, thereby inhibiting proliferation of hormone receptor‑positive breast cancer cells in postmenopausal patients.

Letrozol Teva may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any new symptoms.

Common Side Effects

• Hot flashes: transient increase in body temperature.
• Joint and muscle pain: arthralgia or myalgia.
• Fatigue: general feeling of tiredness.
• Nausea: mild gastrointestinal upset.
• Headache: occasional mild to moderate pain.
• Increased cholesterol: elevation of serum lipid levels.

Serious or Rare Side Effects

• Osteoporosis or bone fractures: decreased bone mineral density.
• Severe liver injury: marked elevation of transaminases.
• Deep vein thrombosis or pulmonary embolism: clot formation.
• Cardiovascular events: hypertension or myocardial infarction.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Vision changes: blurred vision or ocular disturbances.

Before initiating Letrozol Teva, clinicians should assess patient risk factors and monitor relevant parameters.

• Bone health assessment: baseline DEXA scan and periodic monitoring.
• Liver function monitoring: check transaminases before and during therapy.
• Lipid profile evaluation: assess cholesterol levels regularly.
• Cardiovascular risk review: monitor blood pressure and cardiac status.
• Pregnancy contraindication: avoid use in pregnant or nursing women; effective contraception required.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Letrozol Teva can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase letrozole plasma levels.
• Estrogen‑containing hormone therapy: antagonizes therapeutic effect.
• Live vaccines: reduced immune response due to hormonal modulation.

Moderate Interactions (Monitor Closely)

• Cholesterol‑lowering agents (e.g., statins): may require lipid monitoring.
• Anticoagulants (e.g., warfarin): monitor INR for potential changes.
• Antidepressants (SSRIs): observe for additive fatigue or mood effects.